KBP Bioscience

KBP Bioscience is a global, clinical-stage biotechnology company focused on the discovery and development of innovative small molecule therapeutics for cardiorenal and infectious diseases. The company's lead program, ocedurenone (KBP-5074), is a next-generation non-steroidal mineralocorticoid receptor antagonist (nsMRA) that was acquired by AstraZeneca in 2023 for its potential in treating uncontrolled hypertension and chronic kidney disease. KBP utilizes its proprietary integrated R&D platform to identify compounds with optimized pharmacokinetic profiles and improved safety. The company maintains a pipeline of candidates targeting unmet needs in respiratory and anti-infective medicine, including KBP-7072 for bacterial pneumonia. With operations in both the United States and China, KBP bridges global resources to accelerate drug development. The company is led by an experienced management team with a track record in global clinical development and regulatory affairs.